These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17230419)

  • 1. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing.
    Marr N; Luu RA; Fernandez RC
    J Infect Dis; 2007 Feb; 195(4):585-8. PubMed ID: 17230419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance.
    Marr N; Shah NR; Lee R; Kim EJ; Fernandez RC
    PLoS One; 2011; 6(6):e20585. PubMed ID: 21695123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Bordetella pertussis and the complement inhibitor factor H.
    Amdahl H; Jarva H; Haanperä M; Mertsola J; He Q; Jokiranta TS; Meri S
    Mol Immunol; 2011 Jan; 48(4):697-705. PubMed ID: 21167605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bordetella pertussis isolates vary in their interactions with human complement components.
    Brookes C; Freire-Martin I; Cavell B; Alexander F; Taylor S; Persaud R; Fry N; Preston A; Diavatopoulos D; Gorringe A
    Emerg Microbes Infect; 2018 May; 7(1):81. PubMed ID: 29739922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bordetella pertussis acquires resistance to complement-mediated killing in vivo.
    Pishko EJ; Betting DJ; Hutter CS; Harvill ET
    Infect Immun; 2003 Sep; 71(9):4936-42. PubMed ID: 12933835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BapC autotransporter protein is a virulence determinant of Bordetella pertussis.
    Noofeli M; Bokhari H; Blackburn P; Roberts M; Coote JG; Parton R
    Microb Pathog; 2011 Sep; 51(3):169-77. PubMed ID: 21554944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A simplified method for the assessment of C1 esterase inhibitor function].
    Deguchi M; Takemura S; Ueda M; Kasamatsu Y; Yanagida K; Fukuda W; Okamoto M; Onodera H; Sugino S; Kondo M
    Ryumachi; 1990 Jun; 30(3):166-71. PubMed ID: 2244251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the complement cascade by Bordetella pertussis.
    Barnes MG; Weiss AA
    FEMS Microbiol Lett; 2003 Mar; 220(2):271-5. PubMed ID: 12670691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement evasion by Bordetella pertussis: implications for improving current vaccines.
    Jongerius I; Schuijt TJ; Mooi FR; Pinelli E
    J Mol Med (Berl); 2015 Apr; 93(4):395-402. PubMed ID: 25686752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of C1 inhibitor by Bordetella pertussis virulence associated gene 8 results in C2 and C4 consumption away from the bacterial surface.
    Hovingh ES; van den Broek B; Kuipers B; Pinelli E; Rooijakkers SHM; Jongerius I
    PLoS Pathog; 2017 Jul; 13(7):e1006531. PubMed ID: 28742139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract.
    Elder KD; Harvill ET
    Infect Immun; 2004 Oct; 72(10):5919-24. PubMed ID: 15385494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virulence of a Bordetella pertussis strain expressing a mutant adenylyl cyclase with decreased calmodulin affinity.
    Oldenburg DJ; Gross MK; Smith AL; Storm DR
    Microb Pathog; 1993 Jun; 14(6):489-93. PubMed ID: 8412621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis: a matter of immune modulation.
    de Gouw D; Diavatopoulos DA; Bootsma HJ; Hermans PW; Mooi FR
    FEMS Microbiol Rev; 2011 May; 35(3):441-74. PubMed ID: 21204863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth phase influences complement resistance of Bordetella pertussis.
    Barnes MG; Weiss AA
    Infect Immun; 2002 Jan; 70(1):403-6. PubMed ID: 11748208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin binding and augmentation of C1 inhibitor activity.
    Caldwell EE; Andreasen AM; Blietz MA; Serrahn JN; VanderNoot V; Park Y; Yu G; Linhardt RJ; Weiler JM
    Arch Biochem Biophys; 1999 Jan; 361(2):215-22. PubMed ID: 9882449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential in vitro expression of the brkA gene in Bordetella pertussis and Bordetella parapertussis clinical isolates.
    Stefanelli P; Sanguinetti M; Fazio C; Posteraro B; Fadda G; Mastrantonio P
    J Clin Microbiol; 2006 Sep; 44(9):3397-400. PubMed ID: 16954284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET.
    Veal-Carr WL; Stibitz S
    Mol Microbiol; 2005 Feb; 55(3):788-98. PubMed ID: 15661004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Basis for Bordetella pertussis Interference with Complement, Coagulation, Fibrinolytic, and Contact Activation Systems: the Cryo-EM Structure of the Vag8-C1 Inhibitor Complex.
    Dhillon A; Deme JC; Furlong E; Roem D; Jongerius I; Johnson S; Lea SM
    mBio; 2021 Mar; 12(2):. PubMed ID: 33758081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virulence Associated Gene 8 of
    Hovingh ES; de Maat S; Cloherty APM; Johnson S; Pinelli E; Maas C; Jongerius I
    Front Immunol; 2018; 9():1172. PubMed ID: 29915576
    [No Abstract]   [Full Text] [Related]  

  • 20. The vir locus and phase-variation in Bordetella pertussis.
    Stibitz S; Aaronson W; Monack D; Falkow S
    Tokai J Exp Clin Med; 1988; 13 Suppl():223-6. PubMed ID: 2908523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.